Specialized immunohistochemical staining approaches utilized during preclinical and clinical drug discovery research provide valuable insights into the location and positioning of immuno-oncology biomarkers within the tumor and the tumor microenvironment (TME).
We deliver powerful multiplex immunohistochemical and RNAscope tissue staining and probing services, using a range of specialized techniques, including automated multiplex immunofluorescence (IF) and colorimetric immunohistochemistry (IHC), and RNAscope (in situ hybridization for mRNA). We were Europe’s first ACD Bio accredited service provider.
Find out how a pragmatic approach to antibody selection and validation can facilitate demonstration of novel and challenging immuno-oncology biomarkers in situ, providing high-value data to complement functional in vitro assay data and inform cancer immunotherapy clinical trial strategy.
Download the poster to learn more.
